Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000689235 | SCV000816876 | pathogenic | Glycogen storage disease due to glucose-6-phosphatase deficiency type IA | 2022-08-23 | criteria provided, single submitter | clinical testing | This sequence change replaces phenylalanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 322 of the G6PC protein (p.Phe322Val). This variant is not present in population databases (gnomAD no frequency). For these reasons, this variant has been classified as Pathogenic. This missense change has been observed in individual(s) with clinical features of glycogen storage disease (Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 568776). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt G6PC protein function. This variant disrupts the p.Phe322 amino acid residue in G6PC. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 11058903, 30890478). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. |
Natera, |
RCV000689235 | SCV002093331 | uncertain significance | Glycogen storage disease due to glucose-6-phosphatase deficiency type IA | 2020-12-15 | no assertion criteria provided | clinical testing |